Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma

Laboratory Investigation

Volumn 83, Issue 7, 2003, Pages 1033-1043

  Okano, Hiroshi ^a   Shiraki, Katsuya ^a   Inoue, Hidekazu ^a   Kawakita, Tomoyuki ^a   Yamanaka, Takenari ^a   Deguchi, Masatoshi ^a   Sugimoto, Kazushi ^a   Sakai, Takahisa ^a   Ohmori, Shigeru ^a   Fujikawa, Katsuhiko ^a   Murata, Kazumoto ^a   Nakano, Takeshi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 8; CASPASE INHIBITOR; CYCLOHEXIMIDE; DACTINOMYCIN; FAS ANTIBODY; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER TISSUE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL SURVIVAL; CYCLOHEXIMIDE; DACTINOMYCIN; DOWN-REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JURKAT CELLS; LIVER; LIVER NEOPLASMS; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTEIN SYNTHESIS INHIBITORS; TUMOR CELLS, CULTURED;

EID: 0042809497     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000079328.76631.28     Document Type: Article

References (61)

1. Barkett M and Gilmore T (1999). Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 18:6910-6924.
2. Barnes PJ and Karin M (1997). Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases. N Eng J Med 336:1066-1107.
3. Bazzani F and Beutler B (1996). The tumor necrosis factor ligand and receptor families. N Eng J Med 334:1717-1725.
4. Beg AA, Sha WC, Bronson RT, Ghosh S, and Baltimore D (1995). Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 376:167-170.
5. Bernard D, Quatannens B, Vandenbunder B, and Abbadie C (2001). Rel/NF-κB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J Biol Chem 276:27322-27328.
6. Bullani RR, Huard B, Viard-Leveugle I, Byers HR, Irmler M, Saurat JH, Tschopp J, and French LE (2001). Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol 117:360-364.
7. Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, Krammer PH, Peter ME, and Dixit VM (1996). FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 271:4961-4965.
8. Chow NH, Hsu PI, Lin XZ, Yang HB, Chan SH, Cheng KS, Huang SM, and Su IJ (1997). Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: An immunohistochemical study. Hum Pathol 28:698-703.
9. Degli-Esposti MA, Dougall WC, Smock PJ, Waugh JY, Smith CA, and Goodwin RG (1997). The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813-820.
10. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, and Grandien A (1999). The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 190:1025-1032.
11. Fujikawa K, Shiraki K, Sugimoto K, Ito T, Yamanaka T, Takase K, and Nakano T (2000). Reduced expression of ICE/caspase1 and CPP32/caspase3 in human hepatocellular carcinoma. Anticancer Res 20:1927-1932.
12. Fulda S, Meyer E, and Debatin KM (2000). Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulation Fas-associated death domain-like interleukin 1-coverting enzyme inhibitory protein expression. Cancer Res 60:3947-3956.
13. Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM, and Wallach D (1997). CASH: A novel caspase homologue with death effector domains. J Biol Chem 272:19641-19644.
14. Griffith TS and Lynch DH (1998). TRAIL: A molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10:559-563.
15. Gura T (1997). How TRAIL kills cancer cells, but not normal cells. Science 277:768.
16. Harper N, Farrow SN, Kaptein A, Cohen GM, and MacFarlane M (2001). Modulation of tumor necrosis apoptosis-inducing ligand-induced NF-κB activation by inhibition of apical caspases. J Biol Chem 276:34743-34752.
17. Hu S, Vincenz C, Jian N, Gentz R, and Dixit VM (1997). I-FLICE: A novel inhibitor of tumor necrosis factor receptor-1 and CD-95-induced apoptosis. J Biol Chem 272:17255-17257.
18. Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S, and Yamamoto T (2000). Tumor necrosis factor receptor-associated factor (TRAF) family: Adapter proteins that mediate cytokine signaling. Exp Cell Res 254:14-24.
19. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, Rimoldi D, French LE, and Tschopp J (1997). Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195.
20. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, and Suzuki A (2000). Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31:1080-1085.
21. Kataoka T, Budd RC, Holler N, Thome M, Martinon F, Irmler M, Burns K, Hahne M, Kennedy N, Kovacsovics M, and Tschopp J (2000). The caspase-8 inhibitor FLIP promoters activation of NF-κB and Erk signaling pathways. Curr Biol 10:640-648.
22. Khoshnan A, Tindell C, Laux I, Bae D, Bennett B, and Nel AE (2000). The NF-kappaB cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol 165:1743-1754.
23. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, and Peter ME (1995). Cytotoxicity-dependent APO-1(Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14:5579-5588.
24. Krammer PH (1999). CD95 (APO-1/Fas)-mediated apoptosis: Live and let die. Adv Immuniol 71:163-210.
25. Krueger A, Baumann S, Krammer PH, and Kirchhoff S (2001). FLICE-inhibitory proteins: Regulators of death receptor-mediated apoptosis. Mol Cell Biol 21:8247-8254.
26. Locksley RM, Killeen N, and Lenardo MJ (2001). The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104:487-501.
27. Medema JP, de Jong D, van Hall T, Melief CJ, and Offringa R (1999). Immune Escape of Tumors In Vivo by Expression of Cellular FLICE-inhibitory Protein. J Exp Med 190:1033-1038.
28. Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, and Peter ME (1997). FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 16:2794-2804.
29. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, and Dixit VM (1996). FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85:817-827.
30. Nagata S (1997). Apoptosis by death factor. Cell 88:355-365.
31. Natoli G, Ianni A, Costanzo A, De Petrillo G, Ilari I, Chirillo P, Balsano C, and Levrero M (1995). Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 11:1157-1164.
32. Perlman H, Pagliari LJ, Georganas C, Mano T, Walsh K, and Pope RM (1999). FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J Exp Med 190:1679-1688.
33. Ponton A, Clement MV, and Stamenkovic I (1996). The CD95 (APO-1/Fas) receptor activates NF-κB independently of its cytotoxic function. J Biol Chem 271:8991-8995.
34. Rayet B and Gelinas C (1999). Aberrant rel/nfkb genes and activity in human cancer. Oncogene 22:6938-6947.
35. Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, Hartley SB, Menon S, Kastekein R, Bazan F, and O'Rarra A (1997). IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 4:571-581.
36. Ryu BK, Lee MG, Chi SG, Kim YW, and Park JH (2001). Increased expression of cFLIP (L) in colonic adenocarcinoma. J Pathol 194:15-19.
37. Schmid RM and Adler G (2000). NF-κB/Rel/κB: Implication in gastrointestinal diseases. Gastroenterology 118:1208-1228.
38. Schulte-Hermann R, Bursch W, Low-Baselli A, Wanger A, and Grasl-Kraupp B (1997). Apoptosis in the liver and its role in hepatocarcinogenesis. Cell Biol Toxicol 13:339-348.
39. Seitz C, Müller P, Krieg RC, Männel DN, and Hehlgans T (2001). A novel p75TNF receptor isoform mediating NFκB activation. J Biol Chem 276:19390-19395.
40. Shi Y, Hsu JH J, Hu L, Gera J, and Lichtenstein A (2002). Signal pathways involved in activation of p70S6 and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem 277:15712-15720.
41. Shiraki K, Takase K, and Nakano T (2002). The emerging role of caspase inhibitors in gastrointestinal cancers. J Gastroenterol 37:323-331.
42. Shu HB, Halpin DR, and Goeddel DV (1997). Casper is a FADD- and caspase-related inducer of apoptosis. Immunity 6:751-763.
43. Soini Y, Virkajärvi N, Letho VP, and Pääkkö P (1996). Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shorter survival. Br J Cancer 73:1025-1030.
44. Srinivasula SM, Ahmad M, Ottilie S, Bullrich F, Banks S, Wang Y, Alnemri TF, Croce CM, Litwack G, Tomaselli KJ, Armstrong RC, and Alnemri ES (1997). FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 272:18542-18545.
45. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, and Galle PR (1996). Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells: A mechanism of immune evasion? Nat Med 2:1361-1366.
46. Sugimoto K, Shiraki K, Ito T, Fujikawa K, Takase K, Tameda Y, Moriyama M, and Nakano T (1999). Expression of functional CD40 in human hepatocellular carcinoma. Hepatology 30:920-926.
47. Suzuki A, Hayashida M, Kawano H, Sugimoto K, Nakano T, and Shiraki K (2000). Hepatocyte growth factor promotes cell survival from Fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology 4:796-802.
48. Takehara T, Liu X, Fujimoto J, Friedman SL, and Takahashi H (2001). Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 34:55-61.
49. Tepper CG and Seldin MF (1999). Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood 94:1727-1737.
50. Thome M, Schneidei P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schröter M, Scaffidi C, Krammer PH, Peter ME, and Tschopp J (1997). Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517-521.
51. Thompson CB (1995). Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462.
52. Thorgeirsson SS, Teramoto T, and Factor VM (1998). Dysregulation of apoptosis in hepatocellular carcinoma. Semin Liver Dis 18:115-122.
53. Thornberry NA and Lazebnik Y (1998). Caspases: Enemies within. Science 281:1312-1316.
54. Vaux DL, Haecker G, and Strasser A (1994). An evolutionary perspective on apoptosis. Cell 76:777-779.
55. Wajant H, Haas E, Schwenzer R, Mühlenbeck F, Kreuz S, Schubert G, Grell M, Smith C, and Scheurich P (2000). Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD). J Biol Chem 275:24357-24366.
56. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, and Baldwin AS Jr (1998). NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP and c-IAP2 to suppress caspase-8 activation. Science 281:1680-1683.
57. Wang J, Lobito AA, Shen F, Hurnung F, Winoto A, and Lenardo MJ (2000). Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. Eur J Immunol 30:155-163.
58. Willems F, Amraoui Z, Vanderheyde N, Verhasselt V, Aksoy E, Scaffidi C, Peter ME, Krammer PH, and Goldman M (2000). Expression of c-FLIPL and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: Inhibition by bisindolylmaleimide. Blood 95:3478-3482.
59. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, and Kojiro M (1998). Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28:68-77.
60. Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, Takase K, Moriyama M, Nakano T, and Suzuki A (2000). Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32:482-490.
61. Yeh WC, Itie A, Elia AJ, Ng M, Shu HB, Wakeham A, Mirtsos C, Suzuki N, Bonnard M, Goeddel DV, and Mak TW (2000). Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 6:633-642.